Tagged with Daiichi

Global Following the appointment of new boards at the US innovative pharma industry body PhRMA, and its European counterpart EFPIA, it is global group the IFPMA’s turn to reveal a new CEO leadership team, with appointees from Pfizer, Roche and Daiichi Sankyo.   As the industry’s biggest global trade group that…

Brazil The latest pharma news from Brazil, including Daiichi Sankyo’s new plant; Bristol Myers Squibb’s re-entry into Brazil’s cardiology market; the Anvisa approval of HIV prevention drug, cabotegravir; Merck’s gamble on the Brazilian obesity market and Novo Nordisk’s patent extension denial.   Japan’s Daiichi Sankyo invests $80 million to expand Brazilian…

Japan Japan is known for its cutting-edge technology, innovative products, and world-class healthcare system. The pharmaceutical industry in Japan is no exception, with many leading companies making significant contributions to global health and wellness. Read on for a rundown of the top 10 Japanese pharmaceutical companies (based on market capitalisation in…

Japan The latest from Japanese pharma, including Takeda’s big profit jump, British Linepharma’s quest to get the first ever induced abortion pill for practical use, Shionogi’s promise to become the first Japanese company to get a COVID-19 vaccine approved, and the Japanese industry’s opposition to the Biden administration’s support for a…

Japan Japan’s pharma market is one of the world’s biggest, with a value of around USD 95 billion, according to figures from the country’s Ministry of Health, Labour and Welfare (MHLW). Japanese firms have a particularly strong standing in their home market, making up six of the country’s top ten pharma…

Taiwan Sheron Lin, president of Daiichi Sankyo Taiwan, elaborates on the affiliate’s tactical positioning in the region and a leading market for clinical trials and new product launches. Lin goes on to share her strategic priorities in carrying out the Japanese company’s global 2025 vision of transforming into an innovative oncology…

China Yuichi Yomasu, president of Daiichi Sankyo China, shares his first impressions of the dynamic but complex Chinese market since he assumed position ten months ago; the strategic importance of the Chinese affiliate to the Group’s overall business, particularly in light of the Group’s transition towards an innovative leader in oncology…

Korea Dae Jung Kim, president of Daiichi Sankyo Korea provides an insight into the rationale behind the company’s focus on the cardiovascular therapeutic area in South Korea. Mr Kim also reveals how Daiichi Sankyo Korea plans to embrace the company’s global strategy of expanding into the new area of oncology.  …

pharma   The Thai pharmaceutical market is growing due to an aging, wealthier local population and a large medical tourism sector. International companies must however adapt their strategies to suit the Thai market; as must domestic concerns. With an estimated value of USD 4.5 billion, Thailand is Southeast Asia’s second largest…

Pharma The president of Daiichi Sankyo France discusses the affiliate’s positioning and future strategy, the challenges for an international pharmaceutical company in France but also why the many strengths of France more than make up for these challenges, and finally, the unique aspects of Daiichi Sankyo’s corporate culture and core values.…

Pharma Antonino Reale, who has managed Daiichi-Sankyo Italy for the last 12 years, explains the reasoning and strategy behind the company’s almost total restructuring in 2013, including how this has given birth to a new, more agile organization with high engagement amongst its employees, as well as where he believes the…

Daiichi Sankyo The general manager of Daiichi Sankyo Turkey discusses his affiliate’s expansion into a regional hub, current strategies for growth in the Turkish market, and the keys behind his affiliates multiple ‘great place to work’ awards.  In 2012, you had made it a goal to develop the Turkish affiliate into a regional…